TQB3616 capsule

DRUG4 trials

Conditions

Advanced MalignanciesDedifferentiated LiposarcomaHR-positive, HER2-negative Breast NeoplasmsMetastatic Breast CancerRecurrent Breast CancerRecurrent/Metastatic Breast Cancer

Phase 1

Clinical Trial for Effect of TQB3616 Capsule on Pharmacokinetics in Healthy Adult Subjects

CompletedNCT05344729

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recurrent/Metastatic Breast Cancer

Start: 2021-07-06End: 2021-08-30Updated: 2022-04-25

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

RecruitingNCT06202261

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Malignancies, Metastatic Breast Cancer, Recurrent Breast Cancer

Start: 2023-04-13End: 2027-10-31Target: 154Updated: 2024-03-12

Phase 2

TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma

TerminatedNCT05496569

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Dedifferentiated Liposarcoma

Start: 2022-08-08End: 2025-09-28Updated: 2025-11-21

Phase 3

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

Active, not recruitingNCT05365178

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.HR-positive, HER2-negative Breast Neoplasms

Start: 2022-07-01End: 2026-06-30Updated: 2026-01-07

Related Papers

The food effect on the pharmacokinetics of TQB3616 capsule in Chinse healthy subjects: a randomized, open-label, single-center, two-period, two-sequence crossover phase I clinical trial

Frontiers in Pharmacology2025-05-30

Efficacy and safety results of TQB2930, a HER2-targeted bispecific antibody combined with chemotherapy in patients with HER2-positive breast cancer (BC) previously treated with ≥2 line treatments: Results from a phase 1b/2 study.

Journal of Clinical Oncology2025-05-28

Preliminary safety and efficacy of TQB2930, a HER2-targeted bispecific antibody in patients with advanced breast cancer: Results from a phase 1b study.

Journal of Clinical Oncology2024-06-013 citations

Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor.

2024-04-241 citations